Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.

Kamura T, Sato S, Iwai K, Czyzyk-Krzeska M, Conaway RC, Conaway JW.

Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10430-5.

2.

The von Hippel-Lindau tumor suppressor gene.

Kondo K, Kaelin WG Jr.

Exp Cell Res. 2001 Mar 10;264(1):117-25. Review.

PMID:
11237528
3.
4.

The von Hippel-Lindau tumor suppressor protein.

Ivan M, Kaelin WG Jr.

Curr Opin Genet Dev. 2001 Feb;11(1):27-34. Review.

PMID:
11163147
5.

von Hippel-Lindau tumor suppressor: not only HIF's executioner.

Czyzyk-Krzeska MF, Meller J.

Trends Mol Med. 2004 Apr;10(4):146-9. Review.

PMID:
15162797
6.
7.

Molecular targets from VHL studies into the oxygen-sensing pathway.

Maynard MA, Ohh M.

Curr Cancer Drug Targets. 2005 Aug;5(5):345-56. Review.

PMID:
16101382
8.

The von Hippel-Lindau tumour suppressor protein: new perspectives.

Ohh M, Kaelin WG Jr.

Mol Med Today. 1999 Jun;5(6):257-63. Review.

PMID:
10366821
9.

Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene.

Levy AP, Levy NS, Iliopoulos O, Jiang C, Kaplin WG Jr, Goldberg MA.

Kidney Int. 1997 Feb;51(2):575-8. Review.

10.

[Von Hippel-Lindau disease].

Shuin T, Ashida S, Yao M, Kanno H.

Nihon Rinsho. 2000 Jul;58(7):1448-54. Review. Japanese.

PMID:
10921322
11.

Von Hippel-Lindau disease: clinical and molecular perspectives.

Clifford SC, Maher ER.

Adv Cancer Res. 2001;82:85-105. Review.

PMID:
11447766
12.

The von Hippel-Lindau tumour suppressor: a multi-faceted inhibitor of tumourigenesis.

Barry RE, Krek W.

Trends Mol Med. 2004 Sep;10(9):466-72. Review. No abstract available.

PMID:
15350900
13.

The pVHL-hIF-1 system. A key mediator of oxygen homeostasis.

Maxwell PH, Pugh CW, Ratcliffe PJ.

Adv Exp Med Biol. 2001;502:365-76. Review.

PMID:
11950150
14.

[Cellular and tissue hypoxia--role of the von Hippel Lindau gene and hypoxia-inducible factor-1].

Sýkora V, Necas E.

Cas Lek Cesk. 2003;142(10):595-8. Review. Czech.

PMID:
14635422
15.

Subcellular dynamics of the VHL tumor suppressor: on the move for HIF degradation.

Khacho M, Lee S.

Future Oncol. 2009 Feb;5(1):85-95. doi: 10.2217/14796694.5.1.85. Review.

PMID:
19243301
16.

Insights into the role of the von Hippel-Lindau gene product. A key player in hypoxic regulation.

Maxwell PH, Pugh CW, Ratcliffe PJ.

Exp Nephrol. 2001;9(4):235-40. Review.

PMID:
11423722
17.

HIF-1: an oxygen response system with special relevance to the kidney.

Maxwell P.

J Am Soc Nephrol. 2003 Nov;14(11):2712-22. Review. No abstract available.

18.

Beyond the hypoxia-inducible factor-centric tumour suppressor model of von Hippel-Lindau.

Roberts AM, Ohh M.

Curr Opin Oncol. 2008 Jan;20(1):83-9. Review.

PMID:
18043261
19.

[Hypoxia, HIF1alpha and estrogen receptor].

Massaad-Massade L.

Bull Cancer. 2004 Sep;91(9):677-83. Review. French.

20.

RINGs of good and evil: RING finger ubiquitin ligases at the crossroads of tumour suppression and oncogenesis.

Lipkowitz S, Weissman AM.

Nat Rev Cancer. 2011 Aug 24;11(9):629-43. doi: 10.1038/nrc3120. Review.

Supplemental Content

Support Center